PO-S02: Research Guide — Dual GIP/GLP-1 Receptor Agonist

PO-S02 is a 39-amino acid synthetic peptide that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is the first molecule in its class to target both incretin receptors simultaneously — a mechanism referred to as "twincretin" activity.

The peptide is based on the native GIP sequence, with modifications engineered to add GLP-1 receptor binding affinity. Key structural features include:

- A C20 fatty diacid moiety attached via a linker at lysine-20, enabling albumin binding and extending the half-life to approximately 5 days - An aminoisobutyric acid (Aib) substitution at position 2 that confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation - Specific amino acid modifications that create balanced affinity for both GIP and GLP-1 receptors

PO-S02 exhibits approximately 5-fold selectivity for the GIP receptor over the GLP-1 receptor, reflecting its GIP-sequence-based design. This contrasts with pure GLP-1 receptor agonists like po-s01, which have no meaningful GIP receptor activity.

PO-S02's dual receptor activity engages complementary metabolic pathways that neither GIP nor GLP-1 agonism achieves alone.

PO-S02 has been evaluated in two major clinical trial programs: SURPASS (metabolic disease-focused) and SURMOUNT (weight management-focused). These trials provide the most robust evidence for the compound's effects.

PO-S02's pharmacokinetic profile supports once-weekly administration:

**Half-life:** Approximately 5 days (116–120 hours), mediated by albumin binding via the C20 fatty diacid moiety. This is comparable to po-s01's half-life of approximately 7 days.

**Time to steady state:** Approximately 4 weeks (after 4 weekly doses), consistent with the 5-day half-life.

**Bioavailability:** Systemic bioavailability is approximately 80% in pharmacokinetic studies. Absorption is relatively slow, with time to maximum concentration (Tmax) of 8–72 hours.

**Dose proportionality:** Exposure increases approximately dose-proportionally across the 5, 10, and 15 mg dose range.

**Metabolism:** PO-S02 is metabolized by proteolytic cleavage, beta-oxidation of the fatty acid moiety, and amide hydrolysis. It is not a substrate for CYP enzymes, minimizing drug-drug interaction risk.

**Elimination:** Primarily via proteolytic degradation. The renal route accounts for a minor fraction of elimination, and no dose adjustment is required for renal impairment.

The clinical trial safety database for po-s02 encompasses thousands of participants across the SURPASS and SURMOUNT programs.

**Gastrointestinal events:** The most common adverse events are GI-related — nausea (12–31%), diarrhea (12–22%), and vomiting (5–13%). These are generally mild to moderate in severity, occur primarily during concentration-escalation, and diminish with continued treatment. The GI profile is consistent with incretin-class effects on gastric motility.

**Hypoglycemia:** Clinically significant hypoglycemia is rare when po-s02 is used without sulfonylureas or insulin. The glucose-dependent mechanism of insulin secretion provides intrinsic protection against low blood sugar.

**Pancreatitis:** Acute pancreatitis has been reported at low rates in clinical trials (<0.2%), consistent with background rates in the study populations. Monitoring for symptoms is recommended.

**Heart rate:** Small increases in heart rate (2–4 bpm) have been observed, consistent with GLP-1 receptor agonist class effects. No clinically meaningful cardiovascular safety signals have been identified.

**Thyroid C-cell concerns:** Incretin-based therapies carry a class-level preclinical signal for thyroid C-cell tumors in rodents. The relevance to humans is uncertain, and no increase in thyroid cancer has been observed in clinical trials to date.

PO-S02 and po-s01 are the two most studied peptides in the GLP-1/incretin space. Their differences are clinically and mechanistically significant:

**Receptor targets:** PO-S01 is a selective GLP-1 receptor agonist. PO-S02 is a dual GIP/GLP-1 receptor agonist with 5-fold selectivity for GIP over GLP-1. This fundamental difference in receptor pharmacology drives their distinct efficacy profiles.

**Body-composition research signal magnitude:** In SURPASS-2 (head-to-head), po-s02 15 mg produced -12.4 kg body-composition research signal vs. -6.2 kg for po-s01 1 mg at 40 weeks. While SURMOUNT-1 used higher po-s02 doses (up to 15 mg) than the po-s01 trials (STEP-1 used 2.4 mg), the absolute body-composition research signal with po-s02 15 mg (-20.9%) exceeds po-s01 2.4 mg (-14.9%).

**Glycemic control:** PO-S02 produced larger HbA1c reductions than po-s01 1 mg across the dose range in SURPASS-2. The dual incretin mechanism appears to provide superior glucose-lowering effects.

**Structure:** PO-S01 is based on the native GLP-1 peptide sequence. PO-S02 is based on the native GIP sequence with engineered GLP-1 receptor cross-reactivity.

**Half-life:** PO-S01 ~7 days; po-s02 ~5 days. Both support weekly concentration planning.

**GI tolerability:** Both share a GI adverse event profile dominated by nausea, diarrhea, and vomiting. Rates are broadly comparable, though direct comparison is complicated by different concentration-escalation schedules.

PO-S02 is actively studied across multiple research domains beyond its established metabolic effects:

**Cardiovascular outcomes:** The SURPASS-CVOT trial is evaluating po-s02's effects on major adverse cardiovascular events (MACE) in patients with T2D and established cardiovascular disease. Results are expected to clarify whether the metabolic improvements translate to hard cardiovascular endpoints.

**Heart failure:** The SUMMIT trial is investigating po-s02 in heart failure with preserved ejection fraction (HFpEF) in patients with metabolic research — a condition with limited treatment options.

**MASH/NASH (metabolic liver disease):** Given the magnitude of body-composition research signal and improvements in insulin sensitivity, po-s02 is under investigation for metabolic dysfunction-associated steatohepatitis (MASH). Early data suggest significant reductions in hepatic fat content and improvements in histological markers of liver inflammation and fibrosis.

**Obstructive sleep apnea:** The SURMOUNT-OSA trial evaluated po-s02 in patients with moderate-to-severe obstructive sleep apnea and metabolic research, with positive results for reducing apnea-hypopnea index (AHI).

**Kidney disease:** CKD-related metabolic dysfunction and diabetic kidney disease are active areas of investigation, driven by po-s02's improvements in glycemic control, body weight, and blood pressure.

**Combination approaches:** Researchers are exploring combinations with other metabolic agents, including amylin analogs (po-c01) and glucagon receptor agonists, to determine whether additional pathways can augment the dual incretin approach.

PO-S02 for research use is available as a lyophilized peptide requiring preparation for in-vitro laboratory work.

**Preparation:** Prepare with an appropriate laboratory diluent for in-vitro use, adding the diluent slowly along the vial wall and swirling gently. Do not shake. The prepared solution should be clear and colorless.

**Storage:** Lyophilized peptide should be stored at -20C or 2-8C. Prepared solution may be held at 2-8C; laboratory stability is typically up to 28 days. Protect from light, and minimize freeze-thaw cycles.

**Concentration ranges in research:** PO-S02's dual GIP/GLP-1 receptor activity is characterized in vitro across a range of concentrations to map receptor binding affinity and downstream signaling potency at each incretin receptor.